Product Information
HUMIRA(CF) PEN 40 MG/0.4 ML is a brand product labeled by AbbVie Inc., priced at $3367.1086 per EA under NDC 00074055402. Its NADAC has been published 401 times since Dec 19, 2018.
Manufacturer
AbbVie Inc.NDC
00074055402
Classification
Brand
Dosage Form
KIT
Effective Date
8/19/2026
Approval Type
Biologic (BLA)
FDA Application
BLA125057On Market Since
3/9/2016
Price Statistics
The NADAC for HUMIRA(CF) PEN 40 MG/0.4 ML has been published 401 times since Dec 19, 2018, and over the history we have for it it has risen 42.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $3367.1086 per EA |
|---|---|
| All-time high | $3371.4911 (Feb 14, 2024) |
| All-time low | $2371.9480 (Dec 19, 2018) |
| 52-week high | $3367.1086 |
| 52-week low | $3362.9817 |
| Median price | $3121.7510 |
| Average price | $3069.7386 |
| Largest weekly change | +8.0% (Jan 11, 2023) |
| Weeks tracked | 401 |
| Tracking since | Dec 19, 2018 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 0% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of HUMIRA(CF) PEN 40 MG/0.4 ML?
The current National Average Drug Acquisition Cost (NADAC) for HUMIRA(CF) PEN 40 MG/0.4 ML, manufactured by AbbVie Inc., is $3367.1086 per EA (NDC 00074055402), effective Aug 19, 2026.
How has the price of HUMIRA(CF) PEN 40 MG/0.4 ML changed over time?
Over the history we have for it, the NADAC for HUMIRA(CF) PEN 40 MG/0.4 ML has risen 42.0%. It has been tracked across 401 weekly CMS publications since Dec 19, 2018.
What are the highest and lowest recorded NADAC prices for HUMIRA(CF) PEN 40 MG/0.4 ML?
Since Dec 19, 2018, the NADAC for HUMIRA(CF) PEN 40 MG/0.4 ML has ranged from a low of $2371.9480 (Dec 19, 2018) to a high of $3371.4911 (Feb 14, 2024), with a median of $3121.7510 per EA.
Are there cheaper alternatives to HUMIRA(CF) PEN 40 MG/0.4 ML?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, HUMIRA(CF) 20 MG/0.2 ML SYRINGE, is $3366.1230 per EA — about 0% below HUMIRA(CF) PEN 40 MG/0.4 ML.
Who manufactures HUMIRA(CF) PEN 40 MG/0.4 ML?
HUMIRA(CF) PEN 40 MG/0.4 ML (NDC 00074055402) is labeled by AbbVie Inc., and CMS classifies it as a brand product.